Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced Modulus ...

Globus Medical, Inc. (NYSE: GMED) will present its latest advancements in orthopedic technology at the 2025 Annual Meeting of ...

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to ...

StockNews.com lowered shares of Globus Medical (NYSE:GMED – Free Report) from a buy rating to a hold rating in a research ...

Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Thursday, March 13th. Roth Capital analyst J.

Medtech company Globus Medical has expanded its spine portfolio by launching its Cohere anterior lumbar interbody fusion spacer and Modulus ALIF blades. The Cohere space is the first porous ...